









FIG. 1


**FIG. 2**

**FIG. 3A**

**FIG. 3B**

**FIG. 4**

**FIG. 5A**

**FIG. 5B**




FIG. 6




FIG. 7




FIG. 8





FIG. 9

A Primary End Point by Achieved Triglyceride Level at 1 Year


Hazard ratio (95% CI):

**No. at Risk**

Placebo	4090	3743	3327	2807	2347	1358
Icosapent Ethyl Triglyceride $\geq$ 150 mg/dL	2364	2276	2085	1775	1473	803
Icosapent Ethyl Triglyceride <150 mg/dL	1325	1277	1179	1040	922	571

B Key Secondary End Point by Achieved Triglyceride Level at 1 Year

Hazard ratio (95% CI):

**No. at Risk**

Placebo	4090	3837	3500	3002	2542	1487
Icosapent Ethyl Triglyceride $\geq$ 150 mg/dL	2364	2319	2171	1875	1579	879
Icosapent Ethyl Triglyceride <150 mg/dL	1325	1300	1218	1096	986	620

FIG. 10




FIG. 11




FIG. 12